Uprosertib is an orally active N-alkylpyrazole AKT inhibitor that induces tumour cell growth arrest in vitro, enhances cisplatin-induced apoptosis, and reduces tumour volume in vivo when combined with platinum-based cytostatics.280. This evidence concerns the gene AKT1 and neoplasm.